New Phesi Analysis of Alzheimer’s Patients Highlights Need for Preventative Approach that Includes Younger Participants


Phesi identified 117,463 patients who participated in disease modifying trials; representing a significant portion of the patient population. The Phesi analysis reveals the decline that occurs in Alzheimer’s patients over a single 12-month period, with the average 72-year-old suffering from Alzheimer’s losing 18% of cognitive function (measured by MMSE) in 12 months.

Read more about the analysis here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.